Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Share-based Compensation (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Share-based Compensation for 7 consecutive years, with $11.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 24.33% to $11.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.1 million through Dec 2025, up 32.72% year-over-year, with the annual reading at $46.1 million for FY2025, 32.72% up from the prior year.
  • Share-based Compensation hit $11.8 million in Q4 2025 for IDEAYA Biosciences, down from $12.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.2 million in Q3 2025 to a low of $1.9 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $6.0 million across 5 years, with a median of $4.8 million in 2023.
  • Biggest five-year swings in Share-based Compensation: soared 153.03% in 2021 and later grew 21.92% in 2025.
  • Year by year, Share-based Compensation stood at $2.1 million in 2021, then soared by 44.14% to $3.0 million in 2022, then soared by 61.28% to $4.8 million in 2023, then soared by 97.69% to $9.5 million in 2024, then rose by 24.33% to $11.8 million in 2025.
  • Business Quant data shows Share-based Compensation for IDYA at $11.8 million in Q4 2025, $12.2 million in Q3 2025, and $11.9 million in Q2 2025.